Joint Effort 2.0 : Evaluation Among General Population

June 1, 2026 updated by: Centre hospitalier de l'Université de Montréal (CHUM)

" Joint Effort 2.0 " Une Application Mobile de prévention et de réduction Des méfaits: évaluation auprès de Consommateurs de Cannabis

This study aims to evaluate a mobile app designed to promote the safe use of cannabis among adult users in Quebec.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
110

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Canada
    • Quebec
      • Montreal, Quebec, Canada
        • Recruiting
        • Université de Montréal
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Aged 18 years old or older
  • Be an active non-medical cannabis user (ie. self reported past month usage)
  • Understand, read and write French
  • Own a smartphone (iPhone)

Exclusion Criteria:

  • None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Joint Effort
Mobile application
Other: Joint Effort
The Joint Effort intervention is available as an iPhone mobile application in French language. It aims to support cannabis users to take action upon their cannabis use.
Active Comparator: Brief normative feedback and standard information
Webpage
Other: Brief normative feedback and standard information
The brief normative feedback is based on the frequency of cannabis use. Participants will also be offered basic reliable non-personalized information on lower-risk cannabis use in the form of official public websites.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Protective Behavioral Strategies for Marijuana
Time Frame: Baseline, 2-weeks, 4-weeks

Adoption of Protective Behavioral Strategies; measured with the Protective Behavioral Strategies for Marijuana scale (PBSM-17).

The French version of the questionnaire translated by Côté et al. (2021) will be used. The 17 items each represent a behavioral protection strategy. They are measured in terms of frequency of use on a six-point Likert-type scale (never, rarely, occasionally, sometimes, often and always).

The total score of the PBSM-17 is obtained by calculating the total score of each item and then converting this raw score into a standardized form (T-score) ranging from 15 to 73. The lower the total score, the lesser the use of PBS.
Baseline, 2-weeks, 4-weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Intention to take action
Time Frame: Baseline, 2-weeks, 4-weeks

Intention to take action on cannabis use is assessed via a three-item French-language questionnaire developed for this study, based on Ajzen's guidelines for measuring Theory of Planned Behavior.

The questionnaire consist of 3 items: 1) "I intend to take action on my cannabis use in the coming month"; 2) "In the coming month, the chances that I will take action on my cannabis use are…"; and 3) "In the coming month, I will take action on my cannabis use." The items are rated on a seven-point Likert scale ranging, respectively, from "strongly disagree" to "strongly agree", "very low" to "very high", and "very unlikely" to "very likely".

The score of intention to change is the sum of the 3 items (possible score range: 3 to 21). The lower the total score, the weaker the intention to take action on CU.
Baseline, 2-weeks, 4-weeks
Cannabis use frequency
Time Frame: Baseline, 4-weeks

Cannabis use frequency is measured by a question adapted from the French version of the Canadian Community Health Survey (CCHS) : "How often did you use cannabis in the past month?".

The answers follows a six-category rating scale: never; one day in the past month; 2-3 days in the past month; 1-2 days per week in the past month; 3-4 days per week in the past month; 5-6 days per week in the past month; and every day.
Baseline, 4-weeks
Severity of Dependence
Time Frame: Baseline

Level of dependence is measured with the Severity of Dependence Scale (french version).

It consists of five items covering different psychological aspects of dependence: feeling of impaired control, anxiety, preoccupations, wish to stop, and compulsive use.

The possible score ranges from 0 to 15. Items 1 to 4 are scored as follows: 0 = never/almost never, 1 = sometimes, 2 = often, and 3 = always/nearly always. Item 5 is scored as follows: 0 = not difficult, 1 = quite difficult, 2 = very difficult, and 3 = impossible.

Previous studies have set empirically derived optimal cut-off scores for cannabis dependence at 2 to 4 or greater.
Baseline

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Engagement
Time Frame: 2-weeks post-intervention usage
UMARS : engagement subscale The User Version of the Mobile Application Rating Scale (uMARS) is a reliable tool for assessing the quality of mHealth apps. It consists of 20 items grouped into 4 quality subscales-engagement, functionality, aesthetics, and information-as well as 1 subjective quality subscale. Each item is rated on a 5-point scale ranging from 1 (inadequate) to 5 (excellent).
2-weeks post-intervention usage

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Centre hospitalier de l'Université de Montréal (CHUM)

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Didier Jutras-Aswad, Université de Montréal
  • Principal Investigator: Sylvie Cossette, Université de Montréal
  • Principal Investigator: Christine Genest, Université de Montréal
  • Principal Investigator: Shalini Lal, Université de Montréal
  • Principal Investigator: Judith Lapierre, Laval University
  • Principal Investigator: Gabrielle Pagé, Université de Montréal
  • Principal Investigator: Jinghui Cheng, Polytechnique Montréal

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 30, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
April 1, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
April 1, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 2, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 10, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 13, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 3, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 1, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2026-13232

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cannabis Use

Clinical Trials on Brief normative feedback and standard information

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings